COPD

Test your COPD IQ with these 8 questions on spirometry in COPD diagnosis, COPD exacerbations and treatment response, when to add ICS, and other topics for PCPs.

Your daily dose of the clinical news you may have missed.

A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.

Conversely, increases in physical activity of just 500 METs/mins/week reduced respiratory ED visits or hospitalizations by 10-14%, according to a Korean study.

Get GOLD Report updates at-a-glance on initiating pharmacotherapy, avoiding exacerbations, treating dyspnea, how to approach using ICS, plus other topics.

Updates in the Global Initiative for Obstructive Lung Disease report include using spirometry values in diagnosis and optimizing inhaled pharmacotherapy.

The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.

Your daily dose of the clinical news you may have missed.

In persons with COPD, use of the anticonvulsants was linked to a 39% increase in risk of severe disease exacerbation requiring hospital admission, study authors reported.

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

Dupilumab reduced COPD exacerbations by more than one-third in the phase 3 NOTUS trial, matching outcomes from the earlier BOREAS study this year.

Your daily dose of the clinical news you may have missed.

Reduced exacerbations, improved lung function, increased QoL, and less use of systemic corticosteroids underscore dupilumab's effects against type 2 inflammation.

Despite a 20-pack year smoking history and frequent respiratory exacerbations, spirometry is preserved in this group of heavy smokers.

Patients with diabetes had a 35% higher risk of COPD compared with those without diabetes, according to new research.

Results of a new study offer additional support for clinical guidelines to favor one therapy over another, authors suggest.

At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.

Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.

“Patients with COPD who have AMI are less aggressively treated than those without COPD," leading to higher in-hospital mortality and long-term mortality,” wrote authors.

Your daily dose of clinical news you may have missed.

Pain is a prominent symptom among persons with COPD yet management is not included in clinical guidelines and current research findings are vague, say study authors.

Dupilumab in patients with uncontrolled COPD reduced annual exacerbations by 30%, a statistically significant and clinically meaningful outcome and a first for a biologic.

Your daily dose of clinical news you may have missed.

The CAPTURE tool was able to identify 50% of primary care patients with COPD who could immediately benefit from treatment; experts say, it's a start.

Your daily dose of clinical news you may have missed.

Among patients with COPD and OSA, those with consistent CPAP compliance over 12 months showed improved lung function and experienced fewer AECOPD.

Prediction of COPD exacerbations was significantly better with a CT biomarker-based model than either exacerbation history or BODE index.

COPD was associated with a 61% increase in risk of death and 13% greater total costs in the year after surgery, according to a new study.

Exacerbation history alone is unlikely to provide clinical utility for predicting future COPD exacerbations and could be associated with a risk of harm, according to new analysis.

Your daily dose of clinical news you may have missed.